Adjunctive treatment with eplerenone reduced 30 day all cause mortality in acute myocardial infarctionEplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure.

Moyer, Carey D MD (commentator)
Berger, Peter B MD (commentator)
Pitt, B
White, H
Nicolau, J
et al,

Duke Clinical Research Institute Durham, North Carolina, USA

Pitt B, White H, Nicolau J, et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005; 46:425–31.PittBWhiteHNicolauJet alEplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure.J Am Coll Cardiol200546425-31Q In patients with acute myocardial infarction (MI) complicated by left ventricular systolic dysfunction (LVSD) and heart failure, does adjunctive treatment with eplerenone reduce morbidity and mortality more than placebo?

For correspondence: Dr B Pitt, University of Michigan School of Medicine, Ann Arbor, MI, USA. [email protected]

Source of funding: Pfizer Inc.

Evidence Based Medicine 11(1):p 14, February 2006.

Clinical impact ratings IM/Ambulatory care ★★★★★★☆ Internal medicine ★★★★★★☆ Cardiology ★★★★★☆☆